[leish-l] Leishmaniasis in Afghanistan (4)

[Fred R. Opperdoes]

At 10:13 -0400 24/05/02, ProMED Digest wrote:
>Date: Thu, 23 May 2002 16:21:18 -0400 (EDT)
>From: ProMED-mail <promed at promed.isid.harvard.edu>
>Subject: PRO/AH/EDR> Leishmaniasis - Afghanistan (04)
>
>LEISHMANIASIS - AFGHANISTAN (04)
>********************************
>A ProMED-mail post
><http://www.promedmail.org>
>ProMED-mail, a program of the
>International Society for Infectious Diseases
><http://www.isid.org>
>
>Date: Wed, 22 May 2002 08:20:53 -0700 (PDT)
>From: Marianne Hopp <mjhopp12 at yahoo.com>
>Source: WHO Disease Outbreak Reports 22 May 2002 [edited]
><http://www.who.int/disease-outbreak-news/n2002/may/22may2002.html>
>
>
>More background information from the WHO on the outbreak of cutaneous
>leishmaniasis
>- -------------------------------------------------------------------------
>In collaboration with the Ministry of Health of Afghanistan and
>nongovernmental organizations including Health Net International (HNI) and
>TODAI [sorry, no expansion available. - Mod.SH], the World Health
>Organization has recently evaluated the situation regarding cutaneous
>leishmaniasis (CL) in Kabul. The situation in Kabul appears to be
>particularly severe, with an estimated 200 000 cases of CL. Although CL is
>not a lethal disease, it carries a high burden of social stigma. Movements
>of populations both within the country and across borders due to the
>consequences of ongoing conflicts are expected to increase the incidence of
>the disease within the coming months.
>
>CL has been endemic in Afghanistan for several years, with foci of zoonotic
>(animal reservoir to man) transmission mainly in the northern provinces and
>with human to human transmission typically in the large cities. An
>emergency plan of action is being developed by WHO and other partners to
>control the situation by the end of 2003, at least in Kabul. Priority
>interventions include provision of impregnated bednets, early treatment of
>cases with first-line drugs, recruitment and training of intervention
>teams, and health education. WHO has already provided drugs for the
>treatment of 35 000 cases. In collaboration with HNI, WHO has also provided
>impregnated bednets for protection against the sandfly vector.
>
>- --
>ProMED-mail
><promed at promedmail.org>
-- 
Fred R. Opperdoes,
Research Unit for Tropical Diseases (TROP) and
Laboratory of Biochemistry (BCHM)
Christian de Duve Institute of Cellular Pathology (ICP)
and Catholic University of Louvain (UCL)
Avenue Hippocrate 74-75, B-1200 Brussels, Belgium

Tel: ++32-2-764.74.39 (secretary) Fax: ++32-2-762.68.53
Tel: ++32-2-764.74.55 (direct)
Voicemail/fax: ++3270705047
E-mail:Opperdoes at trop.ucl.ac.be
Internet: http://www.icp.ucl.ac.be/trop/
           http://www.icp.ucl.ac.be/~opperd/Fred.html